Abstract 42P
Background
The study investigates the potential of OZ-001, a novel 3,4-dihydroquinazoline derivative containing a ureido group, against diverse cancers. Conventional chemotherapy has limited impact on triple-negative breast cancer (TNBC), and targeted TNBC therapies are lacking. OZ-001 is expected to target both signal transducer and activator of transcription 3 (STAT3) inhibition and T-type calcium channel blocking simultaneously.
Methods
The efficacy and potency of OZ-001 were assessed using MDA-MB-231 cells both in vitro and in vivo. Cell-based assays compassing cell viability, apoptosis, protein expression, cell cycle analysis, fluorescence polarization assay (FP), and intracellular calcium levels were conducted. An in vivo xenograft model using MB-231 cells gauged impact of OZ-001 via oral administration (ranging from 15 to 60mg/kg). Preliminary toxicity evaluation of OZ-001 was conducted using an in vivo model with RD rats.
Results
In vitro, OZ-001 displayed substantial does-dependent inhibition of cell viability inducing a remarkable 10-fold increase in apoptotic genes Bax and caspase-3 compared to the control. As a STAT3 inhibitor, OZ-001 effectively disrupted STAT3-STAT3 interactions in the FP assay, and it reduce STAT3 phosphorylation by 90%. As a T-type calcium channel blocker, OZ-001 exhibited the capability to reduce intracellular calcium levels by 50%, resulting in a notable 90% reduction in calcium signaling. In vivo, OZ-001 led to a 50% reduction in tumor size at a dose of 15mg/kg, and an impressive 95% at 60mg/kg (P.O.), compared to the vehicle-treated group, while a 70% reduction in tumor size at a dose of 10 mg/kg (IP) of Paclitaxel was observed. In a single oral dose toxicity evaluation using SD rats, no specific clinical sign or distinctive necropsy findings were observed, even at a dose of 2,000 mg/kg of OZ-001. This indicates its favorable safety profile.
Conclusions
OZ-001 emerges as a promising therapeutic candidate for TNBC, demonstrating exceptional efficacy as an orally active single agent in reducing tumor growth. The preclinical results present an encouraging avenue for further exploration and development of OZ-001 as a viable alternative for addressing TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ONCOZEN Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract